Development of a predictive model for tumour lysis syndrome in patients with acute myeloid leukemia

Published: June 8, 2009
Abstract Views: 202
PDF: 318
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Tumor lysis syndrome (TLS) can be a life threatening complication during induction chemotherapy in patients with acute myeloid leukemia (AML). TLS is characterized by hyperuricemia, hyperkaliemia, hyperphosphatemia, hypocalcemia and acute renal failure. These abnormalities may occur at presentation of AML due to increased catabolism and turn over of leukemic cells, but more frequently TLS is induced by intensive chemotherapy. Acute urate nephropathy is the main cause of renal failure during TLS, but calcium phosphate precipitation may also contribute to impaired renal function.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Montesinos, P. (2009). Development of a predictive model for tumour lysis syndrome in patients with acute myeloid leukemia. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.413